372 related articles for article (PubMed ID: 33384695)
1. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types.
Oyewole-Said D; Konduri V; Vazquez-Perez J; Weldon SA; Levitt JM; Decker WK
Front Immunol; 2020; 11():608024. PubMed ID: 33384695
[TBL] [Abstract][Full Text] [Related]
2. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4: From mechanism to autoimmune therapy.
Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
[TBL] [Abstract][Full Text] [Related]
5. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
6. Stimulatory and Inhibitory Co-signals in Autoimmunity.
Okazaki T; Okazaki IM
Adv Exp Med Biol; 2019; 1189():213-232. PubMed ID: 31758536
[TBL] [Abstract][Full Text] [Related]
7. Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
Kosmaczewska A; Ciszak L; Boćko D; Frydecka I
Arch Immunol Ther Exp (Warsz); 2001; 49(1):39-46. PubMed ID: 11266089
[TBL] [Abstract][Full Text] [Related]
8. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
9. EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis.
Walker LSK
Immunol Lett; 2017 Apr; 184():43-50. PubMed ID: 28216262
[TBL] [Abstract][Full Text] [Related]
10. A transendocytosis perspective on the CD28/CTLA-4 pathway.
Soskic B; Qureshi OS; Hou T; Sansom DM
Adv Immunol; 2014; 124():95-136. PubMed ID: 25175774
[TBL] [Abstract][Full Text] [Related]
11. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice.
Matsumoto T; Sasaki N; Yamashita T; Emoto T; Kasahara K; Mizoguchi T; Hayashi T; Yodoi K; Kitano N; Saito T; Yamaguchi T; Hirata K
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1141-51. PubMed ID: 27055906
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression.
Kosmaczewska A; Bocko D; Ciszak L; Wlodarska-Polinska I; Kornafel J; Szteblich A; Masternak A; Frydecka I
Pathol Oncol Res; 2012 Apr; 18(2):479-89. PubMed ID: 22094905
[TBL] [Abstract][Full Text] [Related]
14. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of CTLA-4-Ig in tolerance induction.
Alegre ML; Fallarino F
Curr Pharm Des; 2006; 12(2):149-60. PubMed ID: 16454732
[TBL] [Abstract][Full Text] [Related]
16. Molecular and Cellular Functions of CTLA-4.
Van Coillie S; Wiernicki B; Xu J
Adv Exp Med Biol; 2020; 1248():7-32. PubMed ID: 32185705
[TBL] [Abstract][Full Text] [Related]
17. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7.
Damle NK; Klussman K; Leytze G; Myrdal S; Aruffo A; Ledbetter JA; Linsley PS
J Immunol; 1994 Mar; 152(6):2686-97. PubMed ID: 7511623
[TBL] [Abstract][Full Text] [Related]
18. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
[TBL] [Abstract][Full Text] [Related]
19. Confusing signals: recent progress in CTLA-4 biology.
Walker LS; Sansom DM
Trends Immunol; 2015 Feb; 36(2):63-70. PubMed ID: 25582039
[TBL] [Abstract][Full Text] [Related]
20. The complexities of CD28 and CTLA-4 signalling: PI3K and beyond.
Ward SG
Arch Immunol Ther Exp (Warsz); 1999; 47(2):69-75. PubMed ID: 10202558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
